The Clinical Relevance of Double Mutations of EGFR with KRAS, or BRAF, or PIK3CA in Non-Small Cell L

• 作 者: NaixinLiang[1]ShanqingLi[1]ZhiyongLiang[2]HuadanXue[3]FangLi[4]Ren-Heidenreich[5]JiasenXu[5]
• 机 构: Department of Thoracic Surgery,Peking Union Medical College Hospital,Beijing, China
• 出 处: 中国医师协会胸外科医师分会2015年会、第六届全国胸外科学术大会暨第八届浙江省胸部肿瘤论坛
• 发表日期: 2015年期

　　Objective:To determine somatic mutations of epidermal growth factor receptor (EGFR)-pathway networks and investigate clinical therapeutic consequence for progression free survival or overall survival in patients with multiple somatic mutations.Methods:Pathology samples of Chinese NSCLC patients were analyzed for EGFR, KRAS, BRAF and PIK3CA mutations by a 70plex liquidchip technology.Patients harboring both EGFR-TKI activating mutations (EAM) and resistant mutations (ERM) were selected for progression-free survival and overall survival studies following erlotinib TKI treatment.The progression-free survival and overall survival of patients with double mutations were compared with those with only one EAM or no mutations in previous studies.